Skip to content

Breakthrough Therapies

The Breakthrough therapies chart is a list of all publicly announced breakthrough therapy designations since the program’s inception in 2012. The chart is updated daily and includes information about each individual agent or trade name of a drug or treatment, the sponsor company, the date of the designation’s public disclosure, the individual agent’s indication, or the broad disease category in which the designation was granted. The interactive search and sort feature lets you filter your results and download the table at any time into an excel format. Click here to learn more about the history of Breakthrough therapies. As of March 31, 2023, the FDA has approved 278* breakthrough therapy designated products and lists that there have been 1342 total requests for the designation with 519** designations granted.

  • Filter by Sponsor(s)

  • Category

  • FDA Status

  • Reset

Trade Name (Agent)

Sponsor

Date of BT Designation Disclosure

Approval Date

Indication

Category

Trade Name (Agent): Avastin (Bevacizumab)

Sponsor: GENENTECH INC

Date of BT Designation Disclosure: 7/18/2018

Approval Date: 5/29/2020

Indication: In combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy

Category: Cancer

Trade Name (Agent): Pegloprastide (AVB-620)

Sponsor: Avelas Biosciences

Date of BT Designation Disclosure: 12/14/2020

Indication: Intraoperative detection and visualization of positive margins during breast cancer surgery.

Category: Cancer

Trade Name (Agent): Zanidatamab

Sponsor: Zymeworks Inc.

Date of BT Designation Disclosure: 11/30/2020

Indication: Treatment for patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).

Category: Cancer

Trade Name (Agent): Zanidatamab

Sponsor: Zymeworks Inc.

Date of BT Designation Disclosure: 11/30/2020

Indication: Treatment for patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).

Category: Cancer

Trade Name (Agent): Sotorasib

Sponsor: Amgen Inc.

Date of BT Designation Disclosure: 12/08/2020

Indication: Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy.

Category: Cancer

Trade Name (Agent): Repotrectinib

Sponsor: Turning Point Therapeutics Inc.

Date of BT Designation Disclosure: 12/08/2020

Indication: "Treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI-naïve). "

Category: Cancer

Trade Name (Agent): Olorofim

Sponsor: F2G Ltd

Date of BT Designation Disclosure: 10/22/2020

Indication: Treatment of Central Nervous System (CNS) coccidioidomycosis refractory or otherwise unable to be treated with standard of care therapy

Category: Infectious Disease

Trade Name (Agent): Vixarelimab

Sponsor: Kiniksa Pharmaceuticals Ltd

Date of BT Designation Disclosure: 11/16/2020

Indication: Treatment of pruritus associated with prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules

Category: Other

Trade Name (Agent): Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)

Sponsor: Regeneron Pharmaceuticals

Date of BT Designation Disclosure: 11/19/2019

Approval Date: 10/14/2020

Indication: Treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients

Category: Infectious Disease

Trade Name (Agent): EBANGA ANSUVIMAB-ZYKL

Sponsor: Ridgeback Biotherapeutics LP

Date of BT Designation Disclosure: 9/06/2019

Approval Date: 12/21/2020

Indication: Treatment for Ebola

Category: Infectious Disease

Trade Name (Agent): Lanifibranor

Sponsor: Inventiva

Date of BT Designation Disclosure: 10/12/2020

Indication: Treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS)

Category: Other

Trade Name (Agent): IMGN632

Sponsor: ImmunoGen, Inc

Date of BT Designation Disclosure: 10/05/2020

Indication: Treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm

Category: Cancer

Trade Name (Agent): Farxiga® (dapagliflozin)

Sponsor: AstraZeneca

Date of BT Designation Disclosure: 10/02/2020

Approval Date: 4/30/2021

Indication: Patients with chronic kidney disease (CKD), with and without type 2 diabetes (T2D)

Category: Other

Trade Name (Agent): MYDICAR

Sponsor: Celladon

Date of BT Designation Disclosure: 4/10/2014

Indication: Heart failure

Category: Cardiovascular

Trade Name (Agent): Rociletinib (CO-1686)

Sponsor: Clovis Oncology

Date of BT Designation Disclosure: 5/19/2014

Indication: NSCLC

Category: Cancer

Trade Name (Agent): CRS-207 and GVAX

Sponsor: Aduro

Date of BT Designation Disclosure: 7/21/2014

Indication: Pancreatic cancer

Category: Cancer

Trade Name (Agent): AP26113

Sponsor: Ariad Pharmaceuticals Inc.

Date of BT Designation Disclosure: 10/02/2014

Indication: ALK-positive NSCLC

Category: Cancer

Trade Name (Agent): SPK-RPE65

Sponsor: Spark Therapeutics

Date of BT Designation Disclosure: 11/06/2014

Indication: Inherited retinal dystrophy (IRD)

Category: Rare Inherited Disorders

Trade Name (Agent): JCAR015

Sponsor: Juno Therapeutics

Date of BT Designation Disclosure: 11/24/2014

Indication: ALL

Category: Cancer

Trade Name (Agent): Ixazomib

Sponsor: Takeda

Date of BT Designation Disclosure: 12/02/2014

Indication: Systemic light-chain (AL) amyloidosis

Category: Other

Trade Name (Agent): Obeticholic acid (OCA)

Sponsor: Intercept

Date of BT Designation Disclosure: 1/29/2015

Indication: Nonalcoholic steatohepatitis (NASH)

Category: Other

Trade Name (Agent): Olipudase alfa

Sponsor: Sanofi/Genzyme

Date of BT Designation Disclosure: 6/04/2015

Indication: Niemann-Pick disease Type B

Category: Rare Inherited Disorders

Trade Name (Agent): Viaskin Peanut

Sponsor: DBV

Date of BT Designation Disclosure: 4/09/2015

Indication: Peanut allergy in children

Category: Other

Trade Name (Agent): Rucaparib

Sponsor: Clovis

Date of BT Designation Disclosure: 4/06/2015

Indication: Ovarian cancer

Category: Cancer

Trade Name (Agent): EBV-CTL

Sponsor: Atara and MSKCC

Date of BT Designation Disclosure: 3/02/2015

Indication: EBV-associated lymphoproliferative disease

Category: Cancer

Trade Name (Agent): Rindopepimut (Rintega)

Sponsor: Celldex

Date of BT Designation Disclosure: 2/23/2015

Indication: Glioblastoma (GBM)

Category: Cancer

Trade Name (Agent): MPDL3280A

Sponsor: Genentech/Roche

Date of BT Designation Disclosure: 2/01/2015

Indication: Non-small cell lung cancer

Category: Cancer

Trade Name (Agent): ACTEMRA (tocilizumab)

Sponsor: Genentech/Roche

Date of BT Designation Disclosure: 6/10/2015

Approval Date: 3/04/2021

Indication: Systemic scerlosis

Category: Other

Trade Name (Agent): SER-109

Sponsor: Seres

Date of BT Designation Disclosure: 6/12/2015

Indication: Clostridium difficile infection (CDI)

Category: Infectious Disease

Trade Name (Agent): BI 1482694

Sponsor: Boehringer Ingelheim

Date of BT Designation Disclosure: 12/18/2015

Indication: Advanced/pre-treated EGFR mutation-positive NSCLC

Category: Cancer

Trade Name (Agent): Pembrolizumab (Keytruda)

Sponsor: Merck

Date of BT Designation Disclosure: 11/02/2015

Indication: Microsatellite Instability-High (MSI-H) metastatic colorectal cancer (mCRC)

Category: Cancer

Trade Name (Agent): Inotuzumab Ozogamicin

Sponsor: Pfizer

Date of BT Designation Disclosure: 10/19/2015

Indication: ALL

Category: Cancer

Trade Name (Agent): RBX2660

Sponsor: Rebiotix, Inc.

Date of BT Designation Disclosure: 10/12/2015

Indication: Recurrent Clostridium difficile (C diff) infection

Category: Infectious Disease

Trade Name (Agent): BMS-663068

Sponsor: BMS

Date of BT Designation Disclosure: 7/21/2015

Indication: HIV-1 in heavily treatment-experienced adult patients

Category: Infectious Disease

Trade Name (Agent): DX-2930 

Sponsor: Dyax

Date of BT Designation Disclosure: 7/07/2015

Indication: Hereditary angioedema (HAE)

Category: Rare Inherited Disorders

Trade Name (Agent): VTS 270

Sponsor: Vtesse

Date of BT Designation Disclosure: 1/06/2016

Indication: Niemann-Pick Type C1 Disease (NPC)

Category: Rare Inherited Disorders

Trade Name (Agent): Lynparza (olaparib)

Sponsor: AstraZeneca

Date of BT Designation Disclosure: 1/27/2016

Indication: Metastatic Castration Resistant Prostate Cancer

Category: Cancer

Trade Name (Agent): NI-0501

Sponsor: Novimmune

Date of BT Designation Disclosure: 3/16/2016

Indication: Primary Hemophagocytic Lymphohistiocytosis (HLH)

Category: Rare Inherited Disorders

Trade Name (Agent): PKC412 (midostaurin)

Sponsor: Novartis

Date of BT Designation Disclosure: 2/19/2016

Indication: Newly-diagnosed FLT3-mutated AML

Category: Cancer

Trade Name (Agent): Durvalumab (MEDI4736)

Sponsor: AstraZeneca

Date of BT Designation Disclosure: 2/17/2016

Indication: PD-L1+ inoperable/metastatic urothelial bladder cancer

Category: Cancer

Trade Name (Agent): Affinity enhanced T-cell therapy

Sponsor: Adaptimmune

Date of BT Designation Disclosure: 2/09/2016

Indication: NY-ESO in synovial sarcoma

Category: Cancer

Trade Name (Agent): Rapastinel (GLYX-13)

Sponsor: Allergan

Date of BT Designation Disclosure: 1/31/2016

Indication: Major Depressive Disorder (MDD)

Category: Other

Trade Name (Agent): Venetoclax

Sponsor: AbbVie Inc., Roche

Date of BT Designation Disclosure: 1/28/2016

Indication: AML combination therapy

Category: Cancer

Trade Name (Agent): Livtencity (Maribavir)

Sponsor: Takeda Pharmaceutical Company Ltd.

Date of BT Designation Disclosure: 1/08/2018

Approval Date: 11/23/2021

Indication: Treatment of adults and pediatric patients 12 years of age and older and weighing at least 35 kg with posttransplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Category: Infectious Disease

Trade Name (Agent): Upadacitinib (ABT-494)

Sponsor: AbbVie Inc.

Date of BT Designation Disclosure: 1/09/2018

Indication: Adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy

Category: Other

Trade Name (Agent): Lenvima (lenvatinib)

Sponsor: Merck and Eisai

Date of BT Designation Disclosure: 1/09/2018

Approval Date: 8/10/2021

Indication: In combination with pembrolizumab for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

Category: Cancer

Trade Name (Agent): Avelumab in combination with Inlyta (axitinib)

Sponsor: EMD Serono and Pfizer

Date of BT Designation Disclosure: 12/21/2017

Indication: Treatment-naïve patients with advanced renal cell carcinoma (RCC)

Category: Cancer

Trade Name (Agent): Monjuvi

Sponsor: MorpoSys

Date of BT Designation Disclosure: 10/23/2017

Approval Date: 7/31/2020

Indication: Relapsed/Refractory DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation

Category: Cancer

Trade Name (Agent): Valoctocogene Roxaparvovec

Sponsor: BioMarin

Date of BT Designation Disclosure: 10/26/2017

Indication: Hemophilia A

Category: Rare Inherited Disorders

Trade Name (Agent): DAS181

Sponsor: Ansun BioPharma

Date of BT Designation Disclosure: 10/10/2017

Indication: Treatment of lower respiratory tract parainfluenza virus (PIV) infection in immunocompromised patients

Category: Infectious Disease

Trade Name (Agent): EB-101

Sponsor: Abeona Therapeutics Inc

Date of BT Designation Disclosure: 8/30/2017

Indication: Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Category: Other

Trade Name (Agent): Methylenedioxymethamphetamine (MDMA)

Sponsor: MAPS

Date of BT Designation Disclosure: 8/28/2017

Indication: PTSD

Category: Other

Trade Name (Agent): Venetoclax

Sponsor: AbbVie Inc., Roche

Date of BT Designation Disclosure: 8/01/2017

Indication: Elderly patients with previously untreated Acute Myeloid Leukemia (AML) who are ineligible for intensive chemotherapy

Category: Cancer

Trade Name (Agent): Imcivree (setmelanotide)

Sponsor: Rhythm Pharmaceutical, Inc.

Date of BT Designation Disclosure: 1/7/2016

Approval Date: 11/27/2020

Indication: Pro-opiomelanocortin (POMC) deficiency obesity and obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway (the MC4 pathway)

Category: Rare Inherited Disorders

Trade Name (Agent): Tonmya (TNX-102 SL)

Sponsor: Tonix Pharmaceuticals

Date of BT Designation Disclosure: 12/19/2016

Indication: PTSD

Category: Other

Trade Name (Agent): ABT-530

Sponsor: AbbVie Inc.

Date of BT Designation Disclosure: 9/30/2016

Indication: genotype 1 HCV patients who have failed to respond to a previous therapy of direct acting antivirals (or DAAs)

Category: Infectious Disease

Trade Name (Agent): OMS721

Sponsor: Omeros

Date of BT Designation Disclosure: 6/13/2017

Indication: Immunoglobulin A (IgA) nephropathy

Category: Other

Trade Name (Agent): Burtomab

Sponsor: Y-mAbs Therapeutics, Inc.

Date of BT Designation Disclosure: 6/07/2017

Indication: Pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis

Category: Cancer

Trade Name (Agent): Balovaptan

Sponsor: Roche

Date of BT Designation Disclosure: 1/29/2018

Indication: Autism spectrum disorder (ASD)

Category: Rare Inherited Disorders

Trade Name (Agent): GMI-1271

Sponsor: GlycoMimetics

Date of BT Designation Disclosure: 5/17/2017

Indication: Adult Relapsed/Refractory Acute Myeloid Leukemia

Category: Cancer

Trade Name (Agent): Vonapanitase

Sponsor: Proteon Therapeutics, Inc.

Date of BT Designation Disclosure: 5/10/2017

Indication: Increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for hemodialysis in patients on or expected to initiate hemodialysis

Category: Other

Trade Name (Agent): Rethymic (RVT-802)

Sponsor: Enzyvant

Date of BT Designation Disclosure: 4/14/2017

Approval Date: 10/8/2021

Indication: Treatment of pediatric patients with congenital athymia.

Category: Rare Inherited Disorders

Trade Name (Agent): Evkeeza (evinacumab-dgnb)

Sponsor: Regeneron Pharmaceuticals Inc.

Date of BT Designation Disclosure: 4/07/2017

Approval Date: 2/11/2021

Indication: Homozygous familial hypercholesterolemia (HOFH)

Category: Rare Inherited Disorders

Trade Name (Agent): Toca 511 & Toca FC

Sponsor: Tocagen

Date of BT Designation Disclosure: 2/23/2017

Indication: Recurrent high grade glioma

Category: Cancer

Trade Name (Agent): AMT-060

Sponsor: uniQure

Date of BT Designation Disclosure: 1/20/2017

Indication: Hemophilia B

Category: Rare Inherited Disorders

Trade Name (Agent): Neridronic acid

Sponsor: Grünenthal and Abiogen Pharma

Date of BT Designation Disclosure: 12/16/2016

Indication: Complex regional pain syndrome (CRPS)

Category: Rare Inherited Disorders

Trade Name (Agent): Acalabrutinib

Sponsor: AstraZeneca

Date of BT Designation Disclosure: 8/01/2017

Indication: Mantle cell lymphoma for patients who have received at least one prior line of therapy

Category: Cancer

Trade Name (Agent): Elbit Imaging

Sponsor: Gamida Cell

Date of BT Designation Disclosure: 10/10/2016

Indication: Nicord

Category: Cancer

Trade Name (Agent): Alecensa (alectinib)

Sponsor: Roche

Date of BT Designation Disclosure: 10/04/2016

Indication: Adult patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor

Category: Cancer

Trade Name (Agent): SL-401

Sponsor: Stemline Therapeutics

Date of BT Designation Disclosure: 8/23/2016

Indication: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) targeting the interleukin-3 receptor (CD123)

Category: Rare Inherited Disorders

Trade Name (Agent): Esketamine

Sponsor: Janssen

Date of BT Designation Disclosure: 8/16/2016

Approval Date: 7/31/2020

Indication: Major depressive disorder with imminent risk for suicide

Category: Other

Trade Name (Agent): Pracinostat

Sponsor: MEI Pharma

Date of BT Designation Disclosure: 8/01/2016

Indication: In combination with azacitidine of patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy

Category: Cancer

Trade Name (Agent): V920

Sponsor: Merck

Date of BT Designation Disclosure: 7/25/2016

Indication: Ebola Zaire

Category: Infectious Disease

Trade Name (Agent): SPK-9001

Sponsor: Pfizer/Spark

Date of BT Designation Disclosure: 7/21/2016

Indication: Hemophilia B.

Category: Rare Inherited Disorders

Trade Name (Agent): Ivacaftor (Kalydeco)

Sponsor: Vertex

Date of BT Designation Disclosure: 2014

Approval Date: 12/29/2014

Indication: CF monotherapy, patients 6 years or older with R117H mutationin CFTR gene

Category: Rare Inherited Disorders

Trade Name (Agent): Ivacaftor (Kalydeco)

Sponsor: Vertex

Date of BT Designation Disclosure: 2014

Approval Date: 3/17/2015

Indication: CF monotherapy, patients 2 years and older with one of the following CFTR gene mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H

Category: Rare Inherited Disorders

Trade Name (Agent): SHP621 (budesonide oral suspension, or BOS)

Sponsor: Shire

Date of BT Designation Disclosure: 6/13/2016

Indication: Eosinophilic esophagitis (EoE)

Category: Rare Inherited Disorders

Trade Name (Agent): PVS-RIPO

Sponsor: Duke Medicine

Date of BT Designation Disclosure: 5/15/2016

Indication: Recurrent glioblastoma multiforme (GBM)

Category: Cancer

Trade Name (Agent): Ivacaftor (Kalydeco)

Sponsor: Vertex

Date of BT Designation Disclosure: 12/15/2012

Indication: CF combination therapy

Category: Rare Inherited Disorders

Trade Name (Agent): Daclatasvir

Sponsor: BMS

Date of BT Designation Disclosure: 4/25/2013

Indication: Hepatitis C combination therapy

Category: Infectious Disease

Trade Name (Agent): SD101

Sponsor: Scioderm

Date of BT Designation Disclosure: 4/29/2013

Indication: Epidermolysis bullosa

Category: Other

Trade Name (Agent): LIVMARLI (maralixibat)

Sponsor: Shire

Date of BT Designation Disclosure: 6/13/2016

Approval Date: 9/29/2021

Indication: Progressive familial intrahepatic cholestasis type 2 (PFIC2)

Category: Rare Inherited Disorders

Trade Name (Agent): Serelaxin 

Sponsor: Novartis

Date of BT Designation Disclosure: 6/21/2013

Indication: Acute heart failure

Category: Cardiovascular

Trade Name (Agent): Drisapersen

Sponsor: GlaxoSmithKline/Prosensa

Date of BT Designation Disclosure: 6/27/2013

Indication: Duchenne muscular dystrophy (DMD)

Category: Rare Inherited Disorders

Trade Name (Agent): BYM338 (Bimagrumab)

Sponsor: Novartis

Date of BT Designation Disclosure: 8/20/2013

Indication: Sporadic inclusion body myositis (sIBM)

Category: Other

Trade Name (Agent): Entinostat

Sponsor: Syndax

Date of BT Designation Disclosure: 9/11/2013

Indication: ER-positive metastatic breast cancer combination

Category: Cancer

Trade Name (Agent): Volasertib

Sponsor: Boehringer Ingelheim

Date of BT Designation Disclosure: 9/17/2013

Indication: AML combination therapy

Category: Cancer

Trade Name (Agent): Grazoprevir/Elbasvir

Sponsor: Merck

Date of BT Designation Disclosure: 10/22/2013

Indication: Hepatitis C

Category: Infectious Disease

Trade Name (Agent): cPMP (ALXN1011)

Sponsor: Alexion Pharmaceuticals Inc.

Date of BT Designation Disclosure: 10/24/2013

Indication: Molybdenum cofactor deficiency (MoCD) type A

Category: Rare Inherited Disorders

Trade Name (Agent): Dabrafenib

Sponsor: GlaxoSmithKline

Date of BT Designation Disclosure: 1/13/2014

Indication: NSCLC w/ BRAF mutation

Category: Cancer

Trade Name (Agent): Esketamine

Sponsor: J&J

Date of BT Designation Disclosure: 1/21/2014

Indication: Treatment resistant depression

Category: Other

Trade Name (Agent): Daclatasvir/asunaprevir combination

Sponsor: BMS

Date of BT Designation Disclosure: 2/24/2014

Indication: Hepatitis C

Category: Infectious Disease

Trade Name (Agent): HTX-011

Sponsor:

Date of BT Designation Disclosure: 6/21/2018

Indication: Postoperative Pain Management

Category: Other

Trade Name (Agent): Zemdri (plazomicin)

Sponsor:

Date of BT Designation Disclosure: 5/23/2017

Indication: Antibacterials addressing multi-drug resistant (MDR) gram-negative infections

Category: Other

Trade Name (Agent): AMT-601

Sponsor: uniQure, uniQure N.V.

Date of BT Designation Disclosure: 6/28/2018

Indication: Patients with severe and moderately severe hemophilia B

Category: Rare Inherited Disorders

Trade Name (Agent): Kisqali (ribociclib)

Sponsor:

Date of BT Designation Disclosure: 6/20/2018

Approval Date: 7/18/2018

Indication: In combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy

Category: Cancer

Trade Name (Agent): Venclexta (venetoclax) + Rituximab

Sponsor:

Date of BT Designation Disclosure: 1/20/2016

Approval Date: 6/08/2018

Indication: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy

Category: Cancer

Trade Name (Agent): Xalkori (crizotinib)

Sponsor:

Date of BT Designation Disclosure: 5/29/2018

Approval Date: 1/14/2021

Indication: Patients with relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive

Category: Cancer

Trade Name (Agent): Xalkori (crizotinib)

Sponsor:

Date of BT Designation Disclosure: 5/29/2018

Indication: Patients with metastatic non-small cell lung cancer with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy

Category: Cancer

Trade Name (Agent): Tafamidis

Sponsor:

Date of BT Designation Disclosure: 5/23/2018

Indication: Transthyretin Cardiomyopathy (ATTR-ACT)

Category: Cardiovascular